YIV-906 --- "Purely" Botanical Drug
Hi friends, just adding this topic about this "Purely" Botanical Drug:
First-in-class drug candidate developed through NFCR funding commences phase IIB clinical trials
NATIONAL FOUNDATION FOR CANCER RESEARCH
NEWS RELEASE: 19 MAY 2020
Three decades of NFCR basic and translational research funding to primary investigator Dr. Yung-Chi Cheng advances new systems biology paradigm for cancer treatment; world-first phase ii multi-regional clinical trial for botanical cancer drug candidate
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer. Being tested in the first line setting is a first-in-class botanical drug candidate, YIV-906 (also known as PHY906 and KD018), whose development has been supported by the National Foundation for Cancer Research (NFCR) for two decades.
Patients began enrolling in the United States and Taiwan, with Hong Kong and Mainland China to follow. If, following these and future Phase III trials, the drug is approved by the U.S. Food and Drug Administration (FDA), it would be the country's first authorization for usage of a purely botanical cancer drug and usher in a new paradigm for drug discovery.
YIV-906 is an immune-enhancing and cytoprotective cancer therapeutic candidate which received orphan drug designation by the FDA in 2018 ... ... ...
Ancient Chinese medicine unlocks new possibilities for cancer treatment
March 13, 2020
The botanical drug YIV-906 (center) is developed from an 1800-year-old Chinese formula and relies on four naturally derived ingredients: licorice, skullcap, peony, and dates. (Photo credit: Andrew Hurley)